Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted
Gilead Sciences held its 2026 Annual Meeting where shareholders re-elected directors, ratified executive pay, and approved an equity incentive plan, while rejecting three shareholder proposals. The company highlighted strong 2025 performance with $20.8 billion in HIV sales, a 53-program clinical pipeline, and upcoming launches including bulevirtide and Trodelvy. Gilead also mentioned recent acquisitions and its capital return plan, which included $4 billion in dividends and $1.9 billion in stock repurchases, alongside initiatives to expand lenacapavir access globally.
https://finance.yahoo.com/sectors/healthcare/articles/gilead-sciences-annual-meeting-directors-204256359.html